MAPT and Huntington disease: Our work demonstrates that NEFL, total-Tau and BRP-39 all have potential as translational, preclinical fluid biomarkers in mouse models of Huntington’s disease (Supplementary Table 1) and gives an indication of the relative disease-related changes, time-courses and CSF to plasma relationships in four mouse models.